# A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

> **NCT01289509** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 42 (actual)

## Conditions studied

- Idiopathic Thrombocytopenia Purpura

## Interventions

- **DRUG:** E5501
- **DRUG:** Drug: E5501

## Key facts

- **NCT ID:** NCT01289509
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-05
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01289509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01289509, "A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01289509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*